Creative Biogene Unveiled Professional Integrating Lentivirus Service for Studies of Promoter Regulation as well as Target Gene Over-expression

New York – Apr 30th, 2018 – Creative Biogene, one of the world’s leading platform for gene discovery, regulation, and function, unveiling professional integrating lentivirus service to offer support for study on promoter regulation, target gene over-expression, silencing of genes, etc.

With a platform named CPLS (Creative Lentiviral Packaging System), we can generate high safety profile and efficiency of gene delivery to virtually all cell types and the whole model organisms.

There are approximately 1,000 drugs in clinical development, more than 3,000 active clinical trials and more than 570,000 patients enrolled, cancer immunotherapy has become a thriving success in the global biotechnology and pharmaceutical industries. The lentiviral vector is a strictly non-infectious and non-replicating gene transfer vector. They have been widely used in translation and basic research and gene therapy.

At present, there are many labs develop vaccinations based on lentiviral vectors. This kind of vaccine is more or less based on the same basic principles of gene transfer vectors except that it is not a complementary gene that is encoded for gene therapy, but rather those vectors encode antigens, which may be of viral, bacterial or parasitic origin, or also cancer antigens. Vaccine vectors also include specific regulation of antigen expression. The main difference with all other vaccine methods is that these vectors target dendritic cells when injected in vivo, which are the main immune cells responsible for initiating a cellular immune response.

With this lentiviral technique, antigen presentation is long-standing, which is the key difference between all other vaccine methods. This continuous endogenous antigen presentation pathway is unique to lentivirus vaccines. Even after the vaccine is injected once, it can induce a strong, diverse and long-term T cell response. Lentiviral vectors are the best vectors for inducing these strong and long-term T cell responses so far.

Lentiviral vector vaccines elicit an innate immune response. In contrast to CAR-T cells that target a single antigen, lentivirus vaccines target a large number of abnormal motifs on the tumor. This is very effective because the tumor is from multiple aspects and not a single attack.

The challenges also come with this kind of application of lentiviral vector. Lentiviral vectors that are commonly used for biological research are still a fairly new vaccine technology. One limitation, because it is new, requires the establishment of clinical trials in the human body, which is a problem of the binding of carriers and human cells. In gene therapy, researchers usually utilize an integrated vector that is consistent with patient genetics and permanently incorporates it into the patient’s chromosomes. While mitosis happens to the patient’s cells, vector’s DNA also replicates.

About Creative Biogene

Creative Biogene is a US-based manufacturer and provider of genomics and proteomics products and services for academic and governmental research institutes, pharmaceutical and biotechnology industry.

Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human condition through biotechnology.

Media Contact
Company Name: Creative Biogene
Contact Person: Wendy Wilson
Email: Send Email
Phone: 6316197922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biogene.com